Related Experiment Video

Updated: Dec 19, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.8K

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort

Hung-Yi Chen1, Jing-Yang Huang2, Wun-Zhih Siao3

  • 1Department of Pharmacy, China Medical University and China Medical University Beigang Hospital, Yunlin County, Taiwan, ROC.

Cardiovascular Diabetology
|June 7, 2020
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly reduced the risk of new-onset arrhythmias (NOA) and all-cause mortality in type 2 diabetes patients. This real-world study confirms SGLT2 inhibitors

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors are known for cardiovascular benefits and reducing heart failure hospitalizations.
  • The association between SGLT2 inhibitors and arrhythmia risk has not been previously studied.
  • This research addresses the gap in understanding SGLT2 inhibitors' impact on arrhythmias.

Purpose of the Study:

  • To investigate the risk of new-onset arrhythmias (NOA) associated with SGLT2 inhibitor use.
  • To evaluate the impact of SGLT2 inhibitors on all-cause mortality.
  • To assess these risks in a real-world clinical setting.

Main Methods:

  • A population-based cohort study using Taiwan's National Health Insurance Research Database.
  • Patients aged 20+ with type 2 diabetes were divided into SGLT2 inhibitor and non-SGLT2 inhibitor groups.
  • Propensity score matching (1:1) was employed to control for confounding factors, including age, sex, and diabetes duration.

Main Results:

  • The study included 79,150 patients in the SGLT2 inhibitor group and 79,150 matched controls.
  • SGLT2 inhibitor use was associated with a significantly lower risk of all-cause mortality (aHR 0.547; P < 0.0001).
  • A reduced risk of new-onset arrhythmias (NOA) was observed in the SGLT2 inhibitor group (aHR 0.830; P = 0.0002).

Conclusions:

  • In real-world practice, SGLT2 inhibitors are linked to decreased all-cause mortality in type 2 diabetes patients.
  • Prescribing SGLT2 inhibitors was associated with a lower risk of new-onset arrhythmias.
  • These findings support the use of SGLT2 inhibitors for managing type 2 diabetes with potential cardioprotective and anti-arrhythmic benefits.
Abstract

Keywords:
ArrhythmiasDiabetes mellitusSodium–glucose co-transporter inhibitors

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.2K
Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

4.2K

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.5K
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
520
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
236
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
339